The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

An Analysis of the PROCLAIM 2007-2012 National Registry

Gregory A. Daniels, MD, PhD
Published Online: 4:15 PM, Tue June 10, 2014
Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry.

Clinical Pearls:
  • IL-2 is an immunotherapy that can give complete responses that last years
  • The database retrospectively looked back over a 5-year period
  • The registry showed that IL-2 still gives an occasional, durable response
  • The registry also showed that clinical factors such as normal LDH and patient performance status is important in determining who will be successful on IL-2
  • Patients with stable disease or did not seem to respond to IL-2 initially had better overall survival than previously thought, according to the registry findings

<<< Back to "Immunotherapy News from ASCO"

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.